拓新药业 (301089)

Tuoxin Pharmaceutical Group Co.,Ltd.

ASZ

Tags

Pharmaceutical ManufacturingSynthetic BiologyMicro and Small Cap StocksNew Private Equity HoldingsHepatitis ConceptMargin Trading and Securities Lending

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 12654.45
  • Circulating A-Shares(W): 9097.63
  • Earnings Per Share(RMB): -0.2400
  • Net Assets Per Share(RMB): 12.0302
  • Operating Revenue(W RMB): 27155.36
  • Total Profit(W RMB): -3650.96
  • Net Profit Attributable to Parent(W RMB): -3016.11
  • Net Profit Growth Rate(%): -1036.53
  • Weighted Return on Equity(%): -1.9600
  • Operating Cash Flow Per Share(RMB): -0.1800
  • Undistributed Profit Per Share(RMB): 5.5891
  • Capital Reserve Per Share(RMB): 4.9082

2. Main Business

The main business covers:

  • Research, production, and sales of nucleoside (acid) APIs and pharmaceutical intermediates.

3. Company Basic Information

  • Company Name: Tuoxin Pharmaceutical Group Co., Ltd.
  • Listing Date: 2021-10-27
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 515 Kelong Avenue, Hongqi District, Xinxiang City, Henan Province, China
  • Website: www.tuoxinpharm.com
  • Company Profile：On December 8, 2011, Lianda Certified Public Accountants Co., Ltd. issued the "Lianda Audit No. [2011] 1487" Audit Report, confirming that as of the audit base date of October 31, 2011, the book net assets of the limited company were 147,607,690.31 yuan. On December 27, 2011, Beijing Longyuan Zhibo Asset Appraisal Co., Ltd. issued the "Longyuan Zhibo Appraisal Report No. [2011] 1066" Asset Appraisal Report, confirming that as of the appraisal base date of October 31, 2011, the assessed value of the limited company's book net assets was 206.5516 million yuan. On December 8, 2011, the limited company held a board meeting and resolved to transform the entire limited company into a joint stock company, renaming it "Xinxiang Tuoxin Biochemical Co., Ltd." Based on the book net assets of 147,607,690.31 yuan confirmed by the "Lianda Audit No. [2011] 1487" Audit Report, it was converted into 60 million shares at a ratio of 1:0.4065, with a par value of 1 yuan per share, and the remaining 87,607,690.31 yuan was transferred to capital reserve. On December 28, 2011, Lianda Certified Public Accountants Co., Ltd. issued the "Lianda Verification No. [2011] 1108" Capital Verification Report, reviewing the situation where the 8 founding shareholders of Tuoxin Biochemical contributed capital with net assets, verifying that all founding shareholders' subscribed capital contributions had been fully paid, and the company's registered capital had been fully received. On February 20, 2012, the Henan Provincial Department of Commerce issued the "Approval on Agreeing to Change Tuoxin Biochemical into a Foreign-invested Joint Stock Company" (Yushang Ziguan [2012] No. 9), approving this overall transformation. On February 23, 2012, the Henan Provincial People's Government issued the "Approval Certificate for Foreign-invested Enterprises of the People's Republic of China" (Shang Wai Zi Yu Fu Zi Zi [2005] No. 0002) to the company. On March 1, 2012, the company obtained the "Business License of Enterprise Legal Person" issued by the Henan Provincial Administration for Industry and Commerce, with registration number 410700400001029.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 ONTARIO INC. General Legal Person 1729.74 19.01
2 Lukoko Enterprise Co., Ltd. General Legal Person 252.98 2.78
3 BNP Paribas - Proprietary Funds QFII 26.51 0.29
4 Nanjing Shengquan Hengyuan Investment Co., Ltd. - Shengquan Hengyuan Flexible Allocation Special No. 2 Private Securities Investment Fund Private Securities Investment Fund 26.00 0.29

5. Concept Sectors

  • Hepatitis Concept
  • Synthetic Biology
  • Margin Trading & Securities Lending
  • Consecutive Losses
  • New Private Placement
  • Micro & Small Cap Stocks

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information